SCHEMBL5507502

SCHEMBL5507502

O=c1c2c(Cl)cccc2nc2n1CCC2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
KDM4E B2RXH2 4/20 0.60
HSD17B10 Q99714 3/20 0.60
CYP1A2 P05177 2/20 0.60
USP2 O75604 1/20 0.60
BCHE P06276 1/20 0.60
CFTR P13569 1/20 0.60
ALOX15 P16050 1/20 0.60
ACHE P22303 1/20 0.60
HKDC1 Q2TB90 1/20 0.60
GOPC Q9HD26 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
POLB P06746 1/20 0.57
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
HDAC6 Q9UBN7 1/20 0.54
RAB9A P51151 7/20 0.49
NPC1 O15118 6/20 0.49
SMN1; SMN2 Q16637 5/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8968573 0.94 POLB (0.65) ALDH1A1KDM4EHSD17B10CYP1A2USP2
SCHEMBL8969257 0.82 POLB (0.50) ALDH1A1KDM4EHSD17B10CYP1A2USP2
SCHEMBL8969895 0.82 ALDH1A1 (0.52) ALDH1A1KDM4EHSD17B10CYP1A2USP2
SCHEMBL5514297 0.79 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10CYP1A2USP2
SCHEMBL8968557 0.78 POLB (0.56) ALDH1A1KDM4EHSD17B10CYP1A2USP2
SCHEMBL24743538 0.78 POLB (0.89) ALDH1A1KDM4EHSD17B10CYP1A2USP2
SCHEMBL8968425 0.77 MEN1 (0.55) ALDH1A1KDM4EHSD17B10CYP1A2USP2
SCHEMBL8968447 0.77 POLB (0.58) ALDH1A1KDM4EHSD17B10CYP1A2USP2
SCHEMBL31243241 0.77 ALDH1A1 (0.62) ALDH1A1KDM4EHSD17B10CYP1A2USP2
Deoxyvasicinone SCHEMBL29359475 0.75 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10CYP1A2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521583-B1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-01-10 EP disclosed
US-7067519-B2 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2006-06-27 US disclosed
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates ACTELION PHARMACEUTICALS, LTD. (CH) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates HCRTR2, HCRTR1, NPY1R ALDH1A1 1416/4885KDM4E 848/4885HSD17B10 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.